All sponsors

Loxo Oncology, Inc. $LLY

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS7
PHASE 3 / 2-36
RECRUITING2
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO43%

Delay Index: of 7 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +3.1 months). See all sponsors →

Open Loxo Oncology, Inc. on the live radar map → 📅 $LLY readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
LIBRETTO-531
NCT04211337
P3Active, not recruitingMedullary Thyroid Cancer2912023-05-22 (+3 mo)
BRUIN CLL-321
NCT04666038
P3Active, not recruitingChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma2382023-08-29 (-4 mo)
BRUIN-CLL-313
NCT05023980
P3Active, not recruitingChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma2822025-07-11 (+8 mo)
BRUIN CLL-322
NCT04965493
P3Active, not recruitingChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma6002026-10 (+12 mo)
BRUIN-CLL-314
NCT05254743
P3RecruitingChronic Lymphocytic Leukemia; Leukemia, Lymphocytic7372027-10 (-5 mo)
BRUIN-MCL-321
NCT04662255
P3Active, not recruitingLymphoma, Mantle-Cell5002027-11 (+39 mo)
Pirtobrutinib
NCT06588478
P2RecruitingChronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma2492028-06